

ThromboGenics Raises €3.1 Million from the Exercise of Warrants

ThromboGenics streamlines its operations via the cross-border merger of ThromboGenics NV and ThromboGenics Ltd

Leuven, Belgium – May 7, 2009 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, today announces that it has raised €3.1 million as the result of the exercise of warrants by a number of the Company's employees. The 597.000 shares created as a result of this warrant exercise are now listed on Euronext Brussels. Following this transaction, ThromboGenics now has 26.327.789 shares outstanding.

ThromboGenics also announces today that it has completed the merger of ThromboGenics NV with its subsidiary ThromboGenics Ltd. ThromboGenics has carried out this merger to streamline its corporate structure and to optimize its tax management. The merger which will have no impact on the operational activities of the Company will lead to important costs savings. Following this merger ThromboGenics NV will control all of the Company's in-house intellectual property and will retain the tax losses carried forward, which were previously held in ThromboGenics Ltd.

- End -

For further information please contact:

ThromboGenics

Chris Buyse, CFO

Tel: + 32 16 75 13 10

chris.buyse@thrombogenerics.com

Citigate Dewe Rogerson

Amber Bielecka/ David Dible/ Nina Enegren

Tel: +44 (0) 207 638 95 71

amber.bielecka@citigatedr.co.uk

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PIGF) for cancer.



ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.